Webinar on December 11 to feature leading KOLs in dermatology and hair loss alongside Absci leadership Phase 1/2a trial now expected to begin in December 2025, ahead of prior guidance VANCOUVER, Wash. and NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the company will host a virtual seminar on December 11, 2025 at 10:00am ET focused on the company’s ABS-201 (anti-PRLR) program for and ...

Absci TodayABSIAbsci$3.62 -0.07 (-1.77%) 52-Week Range$2.01▼$6.33Price Target$7.98Add to WatchlistThe biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a promising trial or a drug that will make it to market—or crash and burn. As a penny stock with a market cap of just $600 million, Absci Corp. NASDAQ: ABSI falls squarely in the high-risk, high-reward category. The compan ...

Core Insights - Absci is advancing ABS-201, an AI-designed therapeutic antibody for treating androgenetic alopecia, with guidance from renowned dermatologists [1][4][5] - Androgenetic alopecia affects approximately 80 million Americans, with current FDA-approved treatments showing limited efficacy [2] - ABS-201 targets prolactin receptors to stimulate hair follicle regeneration, demonstrating superior hair regrowth compared to minoxidil in preclinical studies [3] Company Overview - Absci is a clinical-stage biotech company utilizing generative AI for drug discovery, aiming to create better biologics faster [7][8] - The company’s Integrated Drug Creation™ platform combines AI models with synthetic biology to innovate therapeutics [7] - Absci is headquartered in Vancouver, WA, with additional facilities in New York City and Switzerland [8] Scientific Advisory Board - Dr. Rodney Sinclair and Dr. David Goldberg have joined the ABS-201 Scientific Advisory Board, bringing extensive expertise in dermatology and hair loss [1][4][6] - Dr. Sinclair has over three decades of experience and has authored over 1000 publications in dermatology [4][5] - Dr. Goldberg has nearly four decades of clinical experience and has conducted pivotal research studies in hair loss, including original Minoxidil trials [5][6] Clinical Development - Phase 1/2a clinical trials for ABS-201 are set to begin in early 2026, with initial proof-of-concept data expected in the second half of 2026 [3] - The novel mechanism of action of ABS-201 offers potential for a durable therapy, addressing the limitations of current treatments that require continuous usage [5][6]

Core Insights - Almirall and Absci Corporation are expanding their AI Drug Discovery collaboration to include a second target for dermatological indications, building on the success of their initial collaboration [1][2][4] - The collaboration leverages Absci's Integrated Drug Creation™ platform and Almirall's dermatology expertise to accelerate the development of innovative therapeutics for chronic skin diseases [2][3] - Absci is eligible for up to approximately $650 million in payments across both programs, in addition to royalties on potential product sales [3] Company Overview - Almirall is a global biopharmaceutical company focused on medical dermatology, founded in 1944 and headquartered in Barcelona, with total revenue of €990 million in 2024 and over 2000 employees globally [5][6] - Absci is a clinical-stage biopharmaceutical company that utilizes generative AI for drug discovery, aiming to create better biologics faster [8][9] Collaboration Details - The initial collaboration, announced in November 2023, successfully delivered AI-designed functional antibody leads against a difficult-to-drug target [2][4] - Absci's generative AI platform is combined with wet lab capabilities to design and validate therapeutic candidates, while Almirall leads the preclinical and clinical development [3][4] - The collaboration aims to accelerate innovation in dermatology by utilizing generative AI for new therapeutic approaches [4]

Core Insights - Absci Corporation has transitioned to a clinical-stage biopharmaceutical company with the initiation of Phase 1 trials for ABS-101, the first AI-designed biologic targeting inflammatory bowel disease (IBD) [1][2][3] Group 1: ABS-101 Development - ABS-101 is an investigational anti-TL1A antibody engineered using Absci's generative AI platform, demonstrating high potency and reduced immunogenicity risk, allowing for quarterly subcutaneous dosing [2][4] - The Phase 1 study is randomized, double-blind, and placebo-controlled, enrolling approximately 40 healthy adult participants to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) [2][3] - Interim safety, PK/PD, and immunogenicity data for ABS-101 are expected in the second half of 2025 [2][4] Group 2: Pipeline and Future Prospects - In addition to ABS-101, Absci is advancing ABS-201, an anti-prolactin receptor antibody for androgenetic alopecia, with Phase 1 trials anticipated to begin in early 2026 [3][6] - The company emphasizes the potential of its generative AI platform to accelerate the development of innovative therapeutics, aiming to bring better biologics to patients more quickly [3][5] Group 3: Company Overview - Absci utilizes an Integrated Drug Creation™ platform that combines AI models with synthetic biology to design therapeutics targeting challenging medical conditions [5][6] - The company is headquartered in Vancouver, WA, with additional facilities in New York City and Switzerland, and collaborates with various pharmaceutical and biotech partners to enhance its therapeutic pipeline [6]